Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431950 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
A Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
- 20
- Study locations
NCT01431950 is a Phase 3 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 238 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT01431950, a Phase 3 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of two doses of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.
Conditions Studied
Interventions
- DRUG fluticasone furoate
- DRUG albuterol/salbutamol
Study Locations (20)
Ohio
- GSK Investigational Site - Canton
- GSK Investigational Site - Cincinnati
- GSK Investigational Site - Toledo
California
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Newport Beach
Louisiana
- GSK Investigational Site - Metairie
- GSK Investigational Site - Sunset
Colorado
- GSK Investigational Site - Colorado Springs
Florida
- GSK Investigational Site - Clearwater
Georgia
- GSK Investigational Site - Albany
Kentucky
- GSK Investigational Site - Lexington
Maryland
- GSK Investigational Site - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431950
The ClinicalTrials.gov registry entry for NCT01431950 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which fluticasone furoate is the first listed.
NCT01431950 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT01431950 about?
NCT01431950 is a clinical study titled "Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents". A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of two doses of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.
What is the current status of trial NCT01431950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2011-09. Estimated completion is 2012-10.
What conditions does trial NCT01431950 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01431950?
The interventions under investigation include: fluticasone furoate (DRUG), albuterol/salbutamol (DRUG).
Who is sponsoring clinical trial NCT01431950?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01431950 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.